1. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.
- Author
-
Emi Takashita, Seiya Yamayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Halfmann, Peter, Wilson, Nancy, Ries, Hunter, Richardson, Alex, Bobholz, Max, Vuyk, William, Maddox, Robert, Baker, David A, Friedrich, Thomas C, O'Connor, David H, Uraki, Ryuta, Ito, Mutsumi, Sakai-Tagawa, Yuko, Adachi, Eisuke, and Saito, Makoto
- Subjects
- *
ANTIVIRAL agents , *VIRAL antibodies , *PHARMACODYNAMICS - Abstract
The article informs about the BA.S subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant has become dominant in most countries around the world. Topics incluyde the amino acid substitutions in the receptorbinding domain of the spike protein, which is the major target for vaccines and therapeutic monoclonal antibodies against SARS-CoV-2; and effectiveness of current vaccines and therapeutic monoclonal antibodies against this subvariant will be decreased.
- Published
- 2022
- Full Text
- View/download PDF